ID   Mieliki
AC   CVCL_QW69
SY   MIELIKI
DR   Wikidata; Q54905689
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7630198;
RX   PubMed=7919343;
CC   Doubling time: ~5-6 days (PubMed=7630198).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   1Y1M
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 29-06-23; Version: 6
//
RX   PubMed=7919343; DOI=10.1182/blood.V84.7.2253.2253;
RA   Renard, Nathalie
RA   Duvert, Valerie
RA   Banchereau, Jacques
RA   Saeland, Sem
RT   "Interleukin-13 inhibits the proliferation of normal and leukemic
RT   human B-cell precursors.";
RL   Blood 84:2253-2260(1994).
//
RX   PubMed=7630198;
RA   Renard, Nathalie
RA   Duvert, Valerie
RA   Matthews, David J.
RA   Pages, Marie-Pierre
RA   Magaud, Jean-Pierre
RA   Manel, Anne-Marie
RA   Pandrau-Garcia, Dominique
RA   Philippe, Noel
RA   Banchereau, Jacques
RA   Saeland, Sem
RT   "Proliferation of MIELIKI a novel t(7;9) early pre-B acute
RT   lymphoblastic leukemia cell line is inhibited concomitantly by IL-4
RT   and IL-7.";
RL   Leukemia 9:1219-1226(1995).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler, Hans Gunther
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//